TipRanks Analyst Maintains Buy Rating on Spyre Therapeutics Amid Strong Clinical Updates

TipRanks analyst Sam Slutsky has maintained his Buy rating on Spyre Therapeutics. The associated price target remains at $119.

The decision is based on several factors tied to Merck's TL1A biology and recent clinical updates. Phase 2 success with its TL1A antibody in hidradenitis suppurativa, along with positive Phase 3 induction results in ulcerative colitis, reinforces confidence that TL1A inhibition can drive meaningful efficacy across multiple immune-mediated diseases.

Merck's broad enthusiasm for TL1A across gastrointestinal, dermatologic, and rheumatologic indications supports a significant commercial opportunity directly relevant to Spyre's pipeline. Additionally, Spyre has a solid cash position and multi-year runway, even accounting for expected burn, providing a financial foundation to advance its TL1A programs.

Slutsky covers the Healthcare sector, with an average return of 49.5% and a 54.84% success rate, according to TipRanks. He also maintains Buy ratings on Abivax SA Sponsored ADR and Olema Pharmaceuticals.